Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes

Journal of Gastroenterology

Volumn 49, Issue 11, 2014, Pages 1504-1513

  Yamashita, Naoki ^a   Ohho, Aritsune ^a   Yamasaki, Akihiro ^a   Kurokawa, Miho ^a   Kotoh, Kazuhiro ^b   Kajiwara, Eiji ^a  

^a STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Follow up protocol; Hepatocellular carcinoma; Interferon therapy; Sustained virological response

Indexed keywords

ALPHA FETOPROTEIN; INTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CANCER SCREENING; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE; ADOLESCENT; CARCINOMA, HEPATOCELLULAR; COMPLICATION; EARLY DIAGNOSIS; EVALUATION STUDY; HEPATITIS C, CHRONIC; INCIDENCE; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926634905     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0921-z     Document Type: Article

References (39)

1. Uemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009; 44(suppl 19): 102-7.
2. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346: 1051-5.
3. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999; 131: 174-81.
4. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999; 29: 1124-30.
5. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997; 127: 875-81.
6. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol. 1999; 30: 653-9.
7. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001; 357: 196-7.
8. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C with advanced fibrosis. J Hepatol. 2010; 52: 652-7.
9. Toyoda H, Kumada T, Tokuda A, et al. Long-term follow-up of sustained responders to interferon therapy in patients with chronic hepatitis C. J Viral Hepat. 2000; 7: 414-9.
10. Enokimura N, Shiraki K, Kawakita T, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res. 2003; 23: 593-6.
11. Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005; 40: 148-56.
12. Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol. 2005; 20: 752-8.
13. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007; 27: 186-91.
14. Hirakawa M, Ikeda K, Arase Y, et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med. 2008; 47: 1637-43.
15. Chang KC, Hung CH, Lu SN, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012; 67: 2766-72.
16. Ito Y, Yamamoto N, Nakata R, et al. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol. 2005; 11: 7218-21.
17. Mashitani T, Yoshiji H, Yamazaki M, et al. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J. 2009; 2: 18.
18. Conteduca V, Sansonno D, Russi S, et al. Therapy of chronic hepatitis C virus infection in the era of direct-acting and hosttargeting antiviral agents. J Infect. 2013. doi: 10. 1016/j. jinf. 2013. 08. 019.
19. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16.
20. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatmentnaïve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology. 2013; 58: 1918-29.
21. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol. 2004; 40: 993-9.
22. Urquijo JJ, Diago M, Boadas J, et al. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Ann Hepatol. 2013; 12(1): 30-5.
23. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology. 1994; 19: 1513-20.
24. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 suppl 1): S115-20.
25. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158: 329-37.
26. Colombo M. Natural history and pathogenesis of hepatitis C virusrelated hepatocellular carcinoma. J Hepatol. 1999; 31: 25-30.
27. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998; 28: 930-8.
28. Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol. 2000; 35: 286-95.
29. Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011; 46: 92-100.
30. Sangiovanni A, Colombo E, Radaelli F, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. Am J Gastroenterol. 2001; 96: 1575-80.
31. Taura N, Fukuda S, Ichikawa T, et al. Relationship of a-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis. Exp Ther Med. 2012; 4: 972-6.
32. Hung CH, Lee CM, Wang JH, et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer. 2011; 128: 2344-52.
33. Khattab MA, Eslam M, Mousa YI, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol. 2012; 11: 487-94.
34. Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer. 2002; 95: 331-9.
35. Ohishi W, Kitamoto M, Aikata H, et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol. 2003; 8: 894-900.
36. Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A. 2002; 99: 15584-9.
37. Miki D, Aikata H, Uka K, et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2008; 43: 550-7.
38. Honda T, Miyaaki H, Ichikawa T, et al. Clinical characteristics of hepatocellular carcinoma in elderly patients. Oncol Lett. 2011; 2: 851-4.
39. Singh P, Coskun ZZ, Goode C, et al. Lymphoid neogenesis and immune infiltration in aged liver. Hepatology. 2008; 47: 1680-90.